Ruxolitinib cream highly effective in treatment of cutaneous lichen planus: Study
Arizona: Topical ruxolitinib is highly effective for treating cutaneous lichen planus (LP), according to findings from a small pilot study in the Journal of Investigative Dermatology. The transcriptomic analysis provided confirmation of LP being an interferon-driven disease and the downregulation of interferon-stimulated genes (ISGs) corresponds to disease response.
Lichen planus is an inflammatory skin condition that affects the skin and mucosal surfaces. Cutaneous lichen planus is a clinical type of lichen planus that shares similar features on histopathology. Its symptoms can range from none (uncommon) to intense itch.
Ruxolitinib is an inhibitor of Janus kinase 1/2 that blocks signal transduction of a critical cytokine involved in the pathogenesis of cutaneous LP called interferon-gamma. In the prospective phase II study, Aaron R. Mangold, Department of Dermatology, Mayo Clinic Arizona, and colleagues investigated the efficacy of topical ruxolitinib in cutaneous LP and performed transcriptomic analysis pre-and post-therapy.
The study included 12 patients with cutaneous LP who were applied topical ruxolitinib twice daily for 8 weeks. Primary endpoints were changes in total lesion count and modified Composite Assessment of Index Lesion Severity (mCAILS) score in index treated and untreated index control lesions at week 4.
Key findings of the study include:
- Total lesion count decreased by a median of 50 lesions (interquartile range 25, 723).
- mCAILS scores decreased by a mean difference of 7.6 (standard deviation 8.8) between index treated and control lesions.
- Type I and II interferon pathways were enriched in LP and responsive disease displayed downregulation of interferon-stimulated genes (ISGs).
"Findings revealed that topical ruxolitinib is highly effective in the treatment of cutaneous LP," wrote the authors. "Transcriptomic analysis confirmed LP as an interferon-driven disease and downregulation of ISGs correlated with disease response."
Reference:
The study titled, "Ruxolitinib cream in the treatment of cutaneous lichen planus: A prospective, open-label study," was published in the Journal of Investigative Dermatology.
DOI: https://doi.org/10.1016/j.jid.2022.01.015
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.